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Glycerophospholipids are important components of cellular membranes, required for constructing struc-
tural barriers, and for providing precursors of bioactive lipid mediators. Lysophosphatidic acid acyltrans-
ferases (LPAATs) are enzymes known to function in the de novo glycerophospholipid biosynthetic
pathway (Kennedy pathway), using lysophosphatidic acid (LPA) and acyl-CoA to form phosphatidic acid
(PA). Until now, three LPAATs (LPAAT1, 2, and 3) have been reported from the 1-acyl-glycerol-3-phos-
phate O-acyltransferase (AGPAT) family. In this study, we identiﬁed a fourth LPAAT enzyme, LPAAT4, pre-
viously known as an uncharacterized enzyme AGPAT4 (LPAATd), from the AGPAT family. Although
LPAAT4 was known to contain AGPAT motifs essential for acyltransferase activities, detailed biochemical
properties were unknown. Here, we found that mouse LPAAT4 (mLPAAT4) possesses LPAAT activity with
high acyl-CoA speciﬁcity for polyunsaturated fatty acyl-CoA, especially docosahexaenoyl-CoA (22:6-CoA,
DHA-CoA). mLPAAT4 was distributed in many tissues, with relatively high expression in the brain, rich in
docosahexaenoic acid (DHA, 22:6). mLPAAT4 siRNA in a neuronal cell line, Neuro 2A, caused a decrease in
LPAAT activity with 22:6-CoA, suggesting that mLPAAT4 functions endogenously. siRNA in Neuro 2A cells
caused a decrease in 18:0–22:6 PC, whereas mLPAAT4 overexpression in Chinese hamster ovary (CHO)-
K1 cells caused an increase in this species. Although DHA is considered to have many important functions
for the brain, the mechanism of its incorporation into glycerophospholipids is unknown. LPAAT4 might
have a signiﬁcant role for maintaining DHA in neural membranes. Identiﬁcation of LPAAT4 will possibly
contribute to understanding the regulation and the biological roles of DHA-containing glycerophospho-
lipids in the brain.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Cellular membranes are comprised of glycerophospholipids,
which have many important structural and functional roles for
cells, for example maintaining cellular barriers and acting as
precursors of lipid signaling molecules [1,2]. Tissues contain
distinct contents of glycerophospholipids, such as phosphatidic
acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine
(PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphati-
dylglycerol (PG) and cardiolipin (CL), each with different composi-
tion of fatty acids [1,3].
Glycerophospholipids are ﬁrst formed from glycerol-3-phos-
phate (G3P) through the de novo pathway (Kennedy pathway)
[4]. G3P is converted to lysoPA (LPA) by glycerol-3-phosphate acyl-
transferases (GPATs), and are subsequently transformed to PA by
LPA acyltransferases (LPAATs) [5]. Once different classes of glycer-
ophospholipids are synthesized from the common intermediate
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ing pathway (Lands’ cycle) [6]. In the Lands’ cycle, glycerophospho-
lipids are degraded to lysophospholipids by phospholipase A2s
(PLA2s), and are formed back to glycerophospholipids by lysophos-
pholipid acyltransferases (LPLATs) [2,3,7]. Mammalian LPAATs
were identiﬁed from the 1-acyl-glycerol-3-phosphate O-acyltrans-
ferase (AGPAT) family, and LPLATs of the remodeling pathway
were found from both the AGPAT and the membrane bound
O-acyltransferase (MBOAT) family [2,7].
The AGPAT family members possess highly conserved motifs
[5], and many have been already characterized. LPAAT1, LPAAT2
and LPAAT3 function as LPAATs in the Kennedy pathway [5,8,9].
Other members are reported to function as GPATs, or as LPLATs
of the Lands’ cycle [5,7].
AGPAT4 (LPAATd) is a member of the AGPAT family, and has
highly homology with LPAAT3 (60%). Although structural and
tissue distribution of AGPAT4 is studied in the past [10], little
biochemical information has been reported. We newly found that
AGPAT4 functions as an LPAAT with high selectivity for polyunsat-
urated fatty acyl-CoA, especially docosahexaenoyl-CoA (DHA-CoA,
22:6-CoA). From biochemical characteristics identiﬁed in this man-
uscript, we will rename this enzyme as LPAAT4 according to the
proposed LPLAT nomenclature [7]. Mouse LPAAT4 (mLPAAT4)
was expressed in many tissues, with highest mRNA expression in
the brain, particularly rich in docosahexaenoic acid (DHA, 22:6)-
containing glycerophospholipids [11]. Although DHA is known to
be important for brain functions [11], the mechanism of DHA
incorporation into cellular membrane glycerophospholipids is still
unknown. LPAAT4 might have an important role for maintaining
adequate DHA levels of brain glycerophospholipids.2. Materials and methods
Please see details in the Supplementary text.2.1. Materials
Fetal bovine serum (FBS) was purchased from Life Technologies
(Carlsbad, CA). Ham’s F-12 nutrient mixture, minimal essential
medium (MEM) and geneticin (G418 Disulfate Aqueous Solution)
were obtained from Nacalai Tesque (Kyoto, Japan). 14:0/14:0 PC
was purchased from NOF corporation (Tokyo, Japan). G3P and
DHA were purchased from Sigma (St. Louis, MO). All other glycer-
ophospholipids, lysophospholipids and acyl-CoAs were purchased
from Avanti Polar Lipids (Alabaster, AL). Methanol, chloroform,
acetonitrile and ammonium bicarbonate were purchased from
Wako (Osaka, Japan).2.2. Plasmids and vectors
mLPAAT4 (NCBI accession number NM_026644, registered as
AGPAT4) cDNA was ampliﬁed by PCR with forward 50-CTAGC-
TAGCCACCATGGATTACAAGGATGACGATGACAAGGACCTCATCGGG
CTGCTGAAGTCCC-30, and reverse 30-CCGCTCGAGTCAGTCCGTTT
GTTTCCGTTTGTTGTCG-50 primers using mouse brain as a template.
mLPAAT4 H96A with a mutation in AGPAT motif I (NHX4D motif,
histidine was converted to alanine) was constructed by overlap
extension PCR with forward 50-GGTCCTCAATGCCAAGTTTG-30, and
reverse 50-CAAACTTGGCATTGAGGACC-30 primers. Mouse GPAT1
(mGPAT1) (NCBI accession number NM_0008149) cDNA was
ampliﬁed by PCR with forward 50-CTAGCTAGCCACCATGGATTA-
CAAGGATGACGATGACAAGGAGGAGTCTTCAGTGACAGTTGGC-30,
and reverse 30-CCGCTTAAGCTACAGCACCACAAAACTC-50 primers
using mouse liver as a template. FLAG epitopes (DYKDDDDK) wereattached to the N-terminus. PCR products were ligated into the
pCXN2.1 vector [12] and sequenced.
2.3. Transfection and siRNA
Chinese hamster ovary (CHO)-K1 cells (provided by the RIKEN
BRC through the National Bio-Resource Project of the MEXT, Japan)
were transfected with cDNAs using Lipofectamine 2000 (Life
Technologies). Microsomal proteins were extracted 48 h post-
transfection. For stable overexpression, transfected CHO-K1 cells
were selected with 3 mg/ml geneticin for four days, and were
maintained in 0.3 mg/ml geneticin. siRNAs of mLPAAT4 (ON-TAR-
GETplus SMARTpoolsiRNA, L-051038-01) and a negative control
(D-001810-10) were obtained from Dharmacon. 5 nM siRNA was
transfected using Lipofectamine RNAiMAX reagent (Life Technolo-
gies) into Neuro 2A cells (ATCC, Manassas, VA).
2.4. LPLAT and GPAT activity measurement
0.5 lg microsomal protein was incubated for 10 min at 37 C
with reaction mixtures containing lysophospholipid and acyl-CoAs
(LPLAT activities) or G3P and acyl-CoAs (GPAT activities). Lipids
were extracted by Bligh and Dyer method, and were measured
using liquid chromatography–mass spectrometry (LC–MS).
2.5. Glycerophospholipid composition analysis
CHO-K1 cells were transfected with pCXN2.1 vector, mLPAAT4
cDNA or mLPAAT4 H96A cDNA, and Neuro 2A cells were transfec-
ted with control or mLPAAT4 siRNA. For both cell types, cells were
treated with 50 lM DHA in 2% FBS medium 48 h post-transfection,
and lipids were extracted at various time points by directly adding
methanol to the dishes. Fatty acid composition of PC, PE and PS
were analyzed using LC–MS.
2.6. Reversed phase LC–MS
Glycerophospholipids were separated with Acquity Ultraperfor-
mance LC (UPLC) system (Waters, Milford, MA), and were detected
by TSQ Vantage Triple Stage Quadrupole Mass Spectrometer (Ther-
mo Scientiﬁc, Waltham, MA) with a HESI-II electrospray ionization
source.
2.7. Quantitative PCR analysis
Quantitative PCRs (LightCycler System; Roche Applied Science,
Mannheim, Germany) were performed using FastStart DNA Master
SYBR Green I (Roche Applied Science). mRNA levels were normal-
ized by 36B4, a housekeeping gene. Primers used were: mLPAAT4
forward, CAAGATCAATGCCAGACTCTGCT; mLPAAT4 reverse,
AAACTTGTGATTGAGGACCACGA; 36B4 forward, CTGAGATTCGG-
GATATGCTGTTG; and 36B4 reverse, AAAGCCTGGAAGAAGGAGGT
CTT.
2.8. Confocal microscopy
CHO-K1 cells stably overexpressing FLAG-tagged mLPAAT4
were used to study subcellular localization. mLPAAT4 was detected
using anti-FLAG M2 antibody. ER, mitochondria and Golgi were
visualized by anti-PDI antibody (Cell Signaling Technology,
Danvers, MA), MitoTracker Red CMXRos (Life Technologies) and
anti-GM130 antibody (Abcam, Cambridge, UK), respectively. Con-
focal microscopy was performed with LSM510 Laser Scanning
Microscope (Carl Zeiss, Germany).
720 M. Eto et al. / Biochemical and Biophysical Research Communications 443 (2014) 718–7242.9. Statistics and softwares
Statistical evaluations and analysis of kinetics were performed
with PRISM 5 software (Graphpad Software Inc., La Jolla, CA).
Statistics were calculated by using Student’s t-test, or one-way
analysis of variance (ANOVA) followed by post hoc Tukey’s test.
Kinetics were analyzed by ﬁtting the data to the Michaelis–Menten
equation.2.10. Mice
C57BL6 N mice were obtained from Clea Japan, Inc. (Tokyo,
Japan). Mice were fed with a standard laboratory diet and water
ad libitum. All animal studies were conducted in accordance with
the guidelines for Animal Research at The University of Tokyo
and were approved by the University of Tokyo Ethics Committee
for Animal Experiments.3. Results
3.1. Cloning and tissue distribution of mLPAAT4
Until now, three LPAATs (LPAAT1, LPAAT2 and LPAAT3) have
been reported. We newly identiﬁed a fourth LPAAT enzyme,
previously known as AGPAT4 (NM_026644). From the biochemical
characteristics described later, we renamed AGPAT4 to LPAAT4.
mLPAAT4 encodes a 378 amino acid protein of 43.8 kDa with 6
transmembrane domains predicted by HMMTOP (http://www.
enzim.hu/hmmtop) [13,14]. Tissue distribution of mLPAAT4 was
analyzed using quantitative PCR, and normalized by 36B4, aA
B
C
Fig. 1. Tissue distribution and subcellular localization of mLPAAT4. (A) mLPAAT4 mRNA
PCR, and normalized by 36B4. Data are shown as the mean + S. E. of three independent ex
Microsomal protein from tissues (10 lg/lane), or CHO-K1 cells transfected with pCXN2.
FLAG-tagged mLPAAT4 (upper) and mLPAAT4 (lower). (C) Immunocytochemical studies
tagged mLPAAT4. mLPAAT4 was detected using anti-FLAG M2 antibody (green). ER, mitoc
and anti-GM130 antibody (red), respectively. Scale bars correspond to 20 lm. Three indhousekeeping gene. mLPAAT4 mRNA was expressed highest in
the brain, followed by lung, stomach and colon (Fig. 1A). Next,
Western blot analysis was performed to study mLPAAT4 protein
expression in various tissues, using anti-mLPAAT4 antibody
(Scrum Inc.) against a C-terminal peptide (IDNKRKQTD). The incon-
sistency between the apparent molecular mass (37 kDa) and the
calculated molecular weight (43.8 kDa), also observed in other
acyltransferases, may be caused by multiple membrane spanning
domains [8,15]. mLPAAT4 was expressed in most tissues, besides
heart, liver and kidney (Fig. 1B). Inconsistent with mRNA expres-
sion levels, highest protein expression was observed in the testis.3.2. Subcellular localization of mLPAAT4
To study subcellular localization of mLPAAT4, CHO-K1 cells
stably overexpressing FLAG-tagged mLPAAT4 were examined by
confocal microscopy. Cells were stained with anti-FLAG M2 anti-
body (Sigma) to detect mLPAAT4, and with organelle markers:
anti-PDI antibody for ER, MitoTracker Red CMXRos for mitochon-
dria and anti-GM130 antibody for Golgi. The expression pattern
of mLPAAT4 was similar to that of the ER marker, but not the mito-
chondria and Golgi markers (Fig. 1C). These results suggest that
mLPAAT4 is mainly localized to the ER when overexpressed in
CHO-K1 cells.3.3. Acyltransferase activities of mLPAAT4
To study the enzymatic activities of mLPAAT4, pCXN2.1 vector,
FLAG-tagged mLPAAT4 or mLPAAT4 H96A were overexpressed in
CHO-K1 cells. Microsomal fractions (100,000g pellet) were usedexpression levels in various tissues of mice (8 weeks) were analyzed by quantitative
periments. (B) Western blot analysis was performed using anti-mLPAAT4 antibody.
1 vector or FLAG-tagged mLPAAT4 (0.5 lg/lane), were loaded. Arrowheads indicate
were performed using CHO-K1 cells stably overexpressing pCXN2.1 vector or FLAG-
hondria and Golgi were visualized by anti-PDI antibody (red), MitoTracker Red (red)
ependent experiments were performed with similar results (B, C).
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mLPAAT4 and mLPAAT4 H96A were similar, conﬁrmed by Western
blot analysis using anti-M2 antibody (Fig. 2A). First, LPLAT
activities were measured using 25 lM 16:0 lysophospholipid and
a mixture of 5 different acyl-CoAs: 1 lM each of 16:0-, 18:1-,
18:2-, 20:4 and 22:6-CoA. mLPAAT4 possessed signiﬁcant LPAAT
activity with high preference for long chain polyunsaturated fatty
acyl-CoA, especially 22:6-CoA (Fig. 2B); however, mLPAAT4 did
not show other LPLAT activities (Fig. S1). mLPAAT4 also did not
possess GPAT activity (Fig. S2A). Activity of mLPAAT4 H96A was
decreased to similar levels to the vector control (Fig. 2B), indicating
that the motif is essential for its activity. These results demon-
strated that LPAAT activities in this assay were caused by mLPAAT4
itself. Activities of mLPAAT4 were also conﬁrmed with 18:0 LPA
and 18:1 LPA as substrates (Fig. S2B).
3.4. Kinetics of mLPAAT4 as an LPAAT
To evaluate substrate binding afﬁnities of mLPAAT4, we exam-
ined LPAAT activities with different concentrations of 22:6-CoA
and LPA. First, LPAAT assays were performed with 25 lM 16:0
LPA and 0–10 lM 22:6-CoA (Fig. 2C). Next, using 10 lM 22:6-
CoA, activities were measured with 0–40 lM 16:0 LPA (Fig. 2D).
Furthermore, we studied LPAAT activities with 10 lM 22:6-CoA
and 0–30 lM 18:0 LPA (Fig. 2E). LPAAT activities were increased
concentration dependently of substrates. At higher concentrations
of 22:6-CoA (>10 lM), 16:0 LPA (>40 lM) or 18:0 LPA (>30 lM),
LPAAT activities were inhibited (data not shown). The maximum37
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Fig. 2. Substrate speciﬁcity of mLPAAT4. (A) Western blot analysis was performed with a
assays (5 lg/lane). Arrowheads indicate FLAG-tagged mLPAAT4 or FLAG-tagged mLPAAT4
different acyl-CoAs (1 lM of 16:0-, 18:1-, 18:2-, 20:4- and 22:6-CoA), using 0.5 lg micro
mLPAAT4 (black bars) or FLAG-tagged mLPAAT4 H96A mutant (gray bars). Data are shown
using 25 lM 16:0 LPA and 0–10 lM 22:6-CoA. (D) LPAAT activities were measured with
10 lM 22:6-CoA and 0–30 lM 18:0 LPA. The maximum velocities (Vmax) and km values c
insets (C–E). (F–H) CHO-K1 cells transfected with pCXN2.1 vector, mLPAAT4 or mLPAAT4
at various time points. The signal intensities of 16:0–22:6 PC (F), 18:0–22:6 PC (G) and 18
mean ± S. E. of triplicate measurements. Three independent experiments were perform
variance (ANOVA) followed by post hoc Tukey’s test; ⁄p < 0.05, ⁄⁄ p < 0.01.velocities and km values calculated from three independent
experiments are shown in the ﬁgures.
3.5. DHA incorporation into mLPAAT4 overexpressing cells
We next investigated howmLPAAT4 inﬂuences DHA-incorpora-
tion into glycerophospholipids, because mLPAAT4 possessed high
activity with 22:6-CoA (DHA-CoA) (Fig. 2B). pCXN2.1 vector,
mLPAAT4 or mLPAAT4 H96A were overexpressed in CHO-K1 cells.
48 h after transfection, cells were treated with 50 lM DHA in 2%
FBS medium, and lipids were extracted at the indicated time
points (0, 1, 3, 6, 9, 12 and 24 h). Glycerophospholipid composition
of PC, PE and PS were analyzed, since PA synthesized through the
de novo pathway is mainly converted to these species. Using
LC–MS, all major species of PC, PE and PS (16:0, 18:0 and 18:1 at
the sn-1 position, 16:0, 18:1, 18:2, 20:4 and 22:6 at the sn-2 posi-
tion) were analyzed. Signal intensities for each species were
summed, and the percentage of each signal was calculated. DHA
addition increased all analyzed DHA-containing glycerophospho-
lipid species. Interestingly, mLPAAT4 overexpression caused an in-
crease in the percentage of 18:0–22:6 PC compared to vector and
mutant transfected cells (Fig. 2G); however, the percentage of
16:0–22:6 PC (Fig. 2F) and 18:1–22:6 PC (Fig. 2H) did not change.
These results are inconsistent with the in vitro activities, which
will be discussed later. DHA-containing PE and PS species (16:0–
22:6, 18:0–22:6 and 18:1–22:6) were also analyzed; however,
none of these were altered by mLPAAT4 overexpression (data
not shown).0
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To conﬁrm endogenous activity of mLPAAT4, siRNA-mediated
knockdown was performed using Neuro 2A cells. siRNA transfec-
tion caused an approximately 90% decrease in mLPAAT4 mRNA
level (Fig. 3A). Western blot analysis showed that endogenous
mLPAAT4 protein was undetectable in mLPAAT4 siRNA transfected
cells (Fig. 3B). siRNA of mLPAAT4 caused an approximately 40% de-
crease in LPAAT activity with 22:6-CoA, suggesting that mLPAAT4
indeed has endogenous activity (Fig. 3C).
Next, we studied the effect of mLPAAT4 siRNA on DHA incorpo-
ration into glycerophospholipids. Neuro 2A cells were transfected
with mLPAAT4 siRNA, and DHA incorporation into PC, PE and PS
were analyzed in the same procedure as in overexpression exper-
iments using CHO-K1 cells. All DHA-containing species showed
an increase by addition of DHA. Intriguingly, the percentage of
18:0–22:6 PC (Fig. 3E) and 18:1–22:6 PC (Fig. 3F) were decreased
by mLPAAT4 knockdown; however, no changes were observed in
the percentage of 16:0–22:6 PC (Fig. 3D). All analyzed PE and PS
species (16:0–22:6, 18:0–22:6 and 18:1–22:6) showed no signiﬁ-
cant differences (data not shown). These results are consistent
with the fatty acid composition changes in mLPAAT4 overexpress-
ing cells, but contradict the in vitro LPAAT activities of mLPAAT4
with 16:0 LPA. This will be discussed later.Remodeling Pathway
(Lands’ Cycle)
Fig. 4. A proposed scheme for the function of mLPAAT4 in the brain. mLPAAT4 is
highly expressed in the brain, and showed LPAAT activity with high preference for
22:6-CoA. DHA-containing PA synthesized by mLPAAT4 is changed to DHA-
containing diacylglycerol (DAG), and is further converted to DHA-containing PC,
PE and PS. mLPAAT4 might be important for synthesizing DHA-containing
glycerophospholipids in the brain.4. Discussion
In this study, we identiﬁed LPAAT4, previously known as
AGPAT4, as a novel type of LPAAT. Although LPAAT4 was already
recognized structurally as a member of the AGPAT family [10],
the LPAAT activity shown in the previous study using 18:1-CoAA
D E
B
Fig. 3. siRNA-mediated knockdown of mLPAAT4 in Neuro 2A cells. (A) Neuro 2A cells
mLPAAT4 were analyzed using quantitative PCR analysis, and normalized by 36B4. (B) W
cells transfected with control or mLPAAT4 siRNA, using anti-mLPAAT4 antibody. mLPA
Arrowheads indicate FLAG-tagged mLPAAT4 (upper) and mLPAAT4 (lower). (C) LPAAT act
with control or mLPAAT4 siRNA, with 25 lM 16:0 LPA and 10 lM 22:6-CoA as substrate
and fatty acid composition of PC was analyzed with LC–MS at various time points. The sig
as the percentage of total PC signal. The percentage of 18:0–22:6 PC and 18:1–22:6 PC
triplicate measurements. Three independent experiments were performed with similar
⁄⁄⁄p < 0.001.was very weak, and the actual substrate of this enzyme was
unknown. Here, we newly demonstrated that mLPAAT4 has LPAAT
activity with high acyl-CoA selectivity for long chain polyunsatu-
rated fatty acyl-CoA, especially 22:6-CoA (Figs. 2B and 4).
mLPAAT3 which has high homology with mLPAAT4 also has LPAATF
C
were transfected with control or mLPAAT4 siRNA, and mRNA expression levels of
estern blot analysis was performed with 10 lg microsomal protein from Neuro 2A
AT4 overexpressed in CHO-K1 cells was used as a positive control (0.5 lg/lane).
ivities were measured using 0.5 lg microsomal protein of Neuro 2A cells transfected
s. (D–F) Control or mLPAAT4 siRNA transfected cells were treated with 50 lM DHA,
nal intensities of 16:0–22:6 PC (D), 18:0–22:6 PC (E) and 18:1–22:6 PC (F) are shown
were decreased by inhibition of mLPAAT4. Data are shown by the mean ± S. E. of
results (A–F). Statistics were calculated with Student’s t-test; ⁄p < 0.05, ⁄⁄p < 0.01,
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mLPAAT3 is reported to possess LPAAT and LPIAT activity, but we
could only observe LPAAT activity of mLPAAT4. Although mLPAAT4
might show other LPLAT activities by changing the experimental
conditions, our data suggest that mLPAAT4 mainly functions as
an LPAAT. mLPAAT4 was distributed in many tissues including
the brain, a tissue abundant in DHA-containing glycerophospholip-
ids.siRNA-mediated knockdown of mLPAAT4 in Neuro 2A cells de-
creased LPAAT activity with 22:6-CoA (Fig. 3C), indicating that
mLPAAT4 functions as an LPAAT endogenously. Compared to the
dramatic decrease in mLPAAT4 mRNA and protein expression
(Fig. 3A and B), the decrease in LPAAT activity was approximately
40%, suggesting the existence of other LPAATs including unknown
enzymes, with activity for 22:6-CoA in this cell line.
Overexpression of mLPAAT4 in CHO-K1 cells caused an increase
in the percentage of 18:0–22:6 PC (Fig. 2G). 16:0–22:6 PC, 18:1–
22:6 PC, and all DHA-containing PE and PS species were unchanged
(Fig. 2F and H). On the other hand, siRNA of mLPAAT4 in Neuro 2A
cells lead to a decrease in the early incorporation rate of 18:1–22:6
PC, and a decrease in 18:0–22:6 PC (Fig. 3E and F); however, 16:0–
22:6 PC and all DHA-containing PE and PS species were not altered
(Fig. 3D). The reason for these results is obscure, since mLPAAT4
showed clear activity towards 16:0 LPA. There are several possibil-
ities to explain the contradictory results. One is that other LPAAT
enzymes are involved in maintaining 16:0–22:6 PC, so the change
in mLPAAT4 expression was not strong enough to inﬂuence its
content. A second is that 16:0–22:6 PC is mainly produced through
the Lands’ cycle. A third is that the level of 16:0–22:6 PC is regu-
lated by the degradation rate. A lipid proﬁling of the spinal cord
of calcium-independent phospholipase A2b (iPLA2b) knockout mice
showed a prominent increase in 16:0–22:6 PC, suggesting the
importance of iPLA2b for degrading these species [16]. Although
further studies are needed to clarify the reason for the partial
change in DHA-containing glycerophospholipids, the change in
18:0–22:6 PC suggests that mLPAAT4 produces DHA-containing
glycerophospholipids in cellular levels. In neural membranes,
DHA is enriched in PE and PS, mainly in the form of 18:0–22:6
[17]. Microsomes from the cerebral cortex synthesizes PS from
18:0–22:6 PC most favorably [18]. PS decarboxylation, a process
which synthesizes PE from PS in the mitochondria, is also reported
to prefer 18:0–22:6 species [19]. Although we could not see
changes in 18:0–22:6 PE and PS in our experiments using cell lines,
the de novo synthesis of 18:0–22:6 glycerophospholipids by
mLPAAT4 might be important for biosynthesis of 18:0–22:6 PE
and PS in the nervous system, where enzymes required for synthe-
sizing these PE and PS species are present.
DHA is believed to have many important roles for the nervous
system. Many animal studies show that an n-3 fatty acid deﬁcient
diet for two generations, which decreases brain and retinal DHA,
impairs visual performance and causes defects in neural functions
[20]. DHA is reported to increase neurite outgrowth in hippocam-
pal neurons [21], and reduced DHA levels are observed in
neurodegenerative diseases, such as Alzheimer’s Disease [11]. It
is controversial whether DHA treatment is clinically effective as a
treatment for Alzheimer’s Disease [22,23], however, recent reports
suggest that DHA might be effective for some patients, those with
the accumulation of intracellular amyloid b oligomers [24]. Future
investigations are needed to conﬁrm if DHA is truly effective, but
these reports suggest a possibility that DHA might lead to treat-
ments for dementia or neurodegenerative diseases.
Although many studies show the importance of DHA for neural
functions, hypothesized to show beneﬁcial effects through the
form of glycerophospholipids, the mechanism of how DHA incor-
porates into brain glycerophospholipids is still unknown. Until
now, the only LPLAT reported to have high preference for 22:6-
CoA was LPAAT3, which has low expression in the brain [9].LPAAT4, which is expressed in the brain, and has high substrate
speciﬁcity for 22:6-CoA, might be one of the key enzymes for syn-
thesizing DHA-containing glycerophospholipids in the nervous
system (Fig. 4). Although further investigations are needed to con-
ﬁrm whether this enzyme actually contributes to synthesis of
DHA-containing glycerophospholipids in vivo, this study might
lead to a new understanding of the molecular mechanism of DHA
incorporation into brain glycerophospholipids, and possibly con-
tribute to new treatments for diseases such as cognitive disorders
or neurodegenerative diseases.
Acknowledgments
We are grateful to Dr. K. Waku (Teikyo University) for valuable
suggestions, and Dr. J.-i. Miyazaki (Osaka University) for supplying
pCXN2. We also thank Drs. Y. Kita and F. Hamano (The University
of Tokyo), and D. Hishikawa, K. Yanagida, T. Harayama, R. Morim-
oto, and all members of our laboratories for valuable suggestions,
and Y. Takahashi for technical assistance (National Center for
Global Health and Medicine).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bbrc.2013.12.043.
References
[1] G. van Meer, D.R. Voelker, G.W. Feigenson, Membrane lipids: where they are
and how they behave, Nat. Rev. Mol. Cell Biol. 9 (2008) 112–124.
[2] T. Shimizu, Lipid mediators in health and disease: enzymes and receptors as
therapeutic targets for the regulation of immunity and inﬂammation, Annu.
Rev. Pharmacol. Toxicol. 49 (2009) 123–150.
[3] A. Yamashita, Y. Hayashi, Y. Nemoto-Sasaki, et al., Acyltransferases and
transacylases that determine the fatty acid composition of glycerolipids and
the metabolism of bioactive lipid mediators in mammalian cells and model
organisms, Prog. Lipid Res. 53 (2013) 18–81.
[4] E.P. Kennedy, S.B. Weiss, The function of cytidine coenzymes in the
biosynthesis of phospholipides, J. Biol. Chem. 222 (1956) 193–214.
[5] R.A. Coleman, D.G. Mashek, Mammalian triacylglycerol metabolism: synthesis,
lipolysis, and signaling, Chem. Rev. 111 (2011) 6359–6386.
[6] W.E. Lands, Metabolism of glycerolipides; a comparison of lecithin and
triglyceride synthesis, J. Biol. Chem. 231 (1958) 883–888.
[7] H. Shindou, T. Shimizu, Acyl-CoA:lysophospholipid acyltransferases, J. Biol.
Chem. 284 (2009) 1–5.
[8] K. Yuki, H. Shindou, D. Hishikawa, T. Shimizu, Characterization of mouse
lysophosphatidic acid acyltransferase 3: an enzyme with dual functions in the
testis, J. Lipid Res. 50 (2009) 860–869.
[9] A. Koeberle, H. Shindou, T. Harayama, T. Shimizu, Role of lysophosphatidic acid
acyltransferase 3 for the supply of highly polyunsaturated fatty acids in TM4
Sertoli cells, FASEB J. 24 (2010) 4929–4938.
[10] B. Lu, Y.J. Jiang, Y. Zhou, et al., Cloning and characterization of murine 1-acyl-
sn-glycerol 3-phosphate acyltransferases and their regulation by PPARa in
murine heart, Biochem. J. 385 (2005) 469–477.
[11] J.R. Marszalek, H.F. Lodish, Docosahexaenoic acid, fatty acid-interacting
proteins, and neuronal function: breastmilk and ﬁsh are good for you, Annu.
Rev. Cell Dev. Biol. 21 (2005) 633–657.
[12] H. Niwa, K. Yamamura, J. Miyazaki, Efﬁcient selection for high-expression
transfectants with a novel eukaryotic vector, Gene 108 (1991) 193–199.
[13] G.E. Tusnady, I. Simon, Principles governing amino acid composition of
integral membrane proteins: application to topology prediction, J. Mol. Biol.
283 (1998) 489–506.
[14] G.E. Tusnady, I. Simon, The HMMTOP transmembrane topology prediction
server, Bioinformatics 17 (2001) 849–850.
[15] D. Hishikawa, H. Shindou, S. Kobayashi, et al., Discovery of a lysophospholipid
acyltransferase family essential for membrane asymmetry and diversity, Proc.
Natl. Acad. Sci. U. S. A. 105 (2008) 2830–2835.
[16] G. Beck, Y. Sugiura, K. Shinzawa, et al., Neuroaxonal dystrophy in calcium-
independent phospholipase A2b deﬁciency results from insufﬁcient
remodeling and degeneration of mitochondrial and presynaptic membranes,
J. Neurosci. 31 (2011) 11411–11420.
[17] H.Y. Kim, Novel metabolism of docosahexaenoic acid in neural cells, J. Biol.
Chem. 282 (2007) 18661–18665.
[18] H.Y. Kim, J. Bigelow, J.H. Kevala, Substrate preference in phosphatidylserine
biosynthesis for docosahexaenoic acid containing species, Biochemistry 43
(2004) 1030–1036.
724 M. Eto et al. / Biochemical and Biophysical Research Communications 443 (2014) 718–724[19] J.H. Kevala, H.Y. Kim, Determination of substrate preference in
phosphatidylserine decarboxylation by liquid chromatography-electrospray
ionization mass spectrometry, Anal. Biochem. 292 (2001) 130–138.
[20] N. Salem Jr., B. Litman, H.Y. Kim, K. Gawrisch, Mechanisms of action of
docosahexaenoic acid in the nervous system, Lipids 36 (2001) 945–959.
[21] F. Calderon, H.Y. Kim, Docosahexaenoic acid promotes neurite growth in
hippocampal neurons, J. Neurochem. 90 (2004) 979–988.
[22] Y. Freund-Levi, M. Eriksdotter-Jonhagen, T. Cederholm, et al., Omega-3 fatty
acid treatment in 174 patients with mild to moderate Alzheimer disease:OmegAD study: a randomized double-blind trial, Arch. Neurol. 63 (2006)
1402–1408.
[23] J.F. Quinn, R. Raman, R.G. Thomas, et al., Docosahexaenoic acid
supplementation and cognitive decline in Alzheimer disease: a randomized
trial, JAMA 304 (2010) 1903–1911.
[24] T. Kondo, M. Asai, K. Tsukita, et al., Modeling Alzheimer’s disease with iPSCs
reveals stress phenotypes associated with intracellular Ab and differential
drug responsiveness, Cell Stem Cell 12 (2013) 487–496.
